GlassScriptPhysician profile
Gil Aaron Weizer
NPI 1730119496
$3,630.47
in general payments reported to CMS, 2019-2025
29 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $408 · 2021: $516 · 2022: $141 · 2023: $305 · 2024: $340 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $960.75 | 2020-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $300.71 | 2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $230.04 | 2023-2025 | Keytruda, Bridion |
| Teleflex LLC | $215.32 | 2021-2025 | Barrigel, Urolift |
| Astellas Pharma US INC | $193.73 | 2019-2025 | Xtandi |
| Coloplast Corp | $191.01 | 2019-2025 | |
| Calyxo, INC. | $184.14 | 2024-2025 | Cvac Aspiration System |
| Neotract INC. | $173.90 | 2019 | |
| Procept Biorobotics Corporation | $150.82 | 2023 | Aquabeam Robotic System |
| Endo USA, INC. | $118.77 | 2024-2025 | Aveed, Xiaflex, Edex |
| Urogen Pharma, INC. | $114.40 | 2021-2025 | |
| Tolmar, INC. | $95.21 | 2024-2025 | Jatenzo |
| Janssen Biotech, INC. | $92.57 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $81.73 | 2019-2025 | Lithovue |
| Novartis Pharmaceuticals Corporation | $62.20 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.14 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.57 | 2025 | |
| Accord Healthcare, INC. | $48.62 | 2025 | |
| Rochester Medical Corporation | $46.10 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $43.33 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $31.55 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $31.04 | 2025 | |
| Blue Earth Diagnostics | $27.17 | 2019 | |
| Lantheus Medical Imaging, INC. | $26.96 | 2024 | |
| Ferring Pharmaceuticals INC. | $24.94 | 2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $24.17 | 2019 | |
| Abbvie INC. | $23.07 | 2025 | |
| Amgen INC. | $13.70 | 2020 | |
| Medtronic USA, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gil Weizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.